Abstract
Cardiovascular complications of anticancer therapies have emerged as a critical problem in public health, especially if we consider that cancer survival rate is increasing in the last years. Cardiotoxicity due to chemotherapy, like treatment with doxorubicin (doxo), is a serious condition, which can evolve to chronic cardiopathy leading to death. Studies focused on signaling activated by …